secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001104659-23-002496
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata closes $30M secured convertible credit from Innoviva at 8%, due Jan 2024
-------------------------------------------------------------------------------

- Gross proceeds $30M from Innoviva Strategic Opportunities LLC, Armata's largest shareholder, at 8% interest, matures Jan 10, 2024.
- Loan converts to common stock upon qualified financing at 15% discount to investors' price; lender option to convert after SEC registration effective at greater of book value or $1.52/share.
- Proceeds used to fund clinical development of AP-PA02 and AP-SA02 and complete cGMP manufacturing facility.
- Loan secured by substantially all assets of Armata and its domestic/foreign material subsidiaries; no warrants issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/0001104659-23-002496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/tm232848d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer